Program
brenipatide
Also written as “Brenipatide” and “LY3537031”.
In Eli Lilly’s own words, LY3537031 (Brenipatide) is a biologic entity that acts as an agonist of both glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide (GLP-1) receptor
. Its studies are mostly in Depressive Disorder, Major · Irritable Bowel Syndrome · Alcoholism · Obesity · Asthma, led by Eli Lilly.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 1916 open or running | phase 3since Oct 13, 2025 | Nov 24, 2020 | Nov 2026phase 1 · NCT06606106 |
- Named in Eli Lilly’s own pipeline as
Brenipatide
, phase 3, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 1 study since Nov 24, 2020.
- Aug 27, 2024Phase 1 study in OverweightNCT06606106 · 302 enrolled · United States
- Sep 3, 20253 phase 1 studiesNCT07165015, NCT07165002, NCT07202871
- Oct 13, 20252 phase 3 studies in AlcoholismNCT07219966, NCT07219953
- Oct 20, 20252 phase 2 studiesNCT07219173, NCT07223840
- Nov 21, 2025Phase 2 study in Bipolar DisorderNCT07286175 · 400 planned · United States, Argentina, Brazil and more
- Jan 29, 2026Named brenipatideINNProposed as its International Nonproprietary Name in WHO's List 134 · before, LY3537031
- Feb 6, 2026Phase 3 study in Depressive Disorder, MajorNCT07412756 · 1,000 planned · United States, Australia, Brazil and more
- Feb 6, 20262 phase 2 studiesNCT07410507, NCT07420283
- Mar 13, 2026Phase 1 study in ObesityNCT07476118 · 150 enrolled · United States
- Apr 16, 20262 phase 2 studies in Irritable Bowel SyndromeNCT07545772, NCT07545759
- Aug 7, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07759245 · 606 planned · United States, Argentina, Austria and more
- Aug 14, 2026Phase 3 study in Depressive Disorder, MajorNCT07775300 · 1,000 planned · United States, Australia, Brazil and more
- Sep 30, 2026Primary completion moved from 2026-07 to 2026-11Date moved laterphase 1 · +4 months · NCT06606106
- Sep 30, 2026Primary completion moved from 2026-08 to 2026-11Date moved laterphase 1 · +3 months · NCT07165002
- Nov 5, 2026Phase 2 study in Depressive Disorder, MajorNCT07928245 · 330 planned · United States, Bulgaria, Hungary and more
Ahead
- Nov 2026Primary completion: phase 1 study in Hepatic InsufficiencyNCT07165002
- Nov 2026Primary completion: phase 1 study in OverweightNCT06606106
- Feb 2027Primary completion: phase 1 study in ObesityNCT07476118
- Feb 2027Primary completion: phase 2 study in SmokingNCT07223840
TargetBeta
“LY3537031 (Brenipatide) is a biologic entity that acts as an agonist of both glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide (GLP-1) receptor”company, read by Claude · source
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| olatorepatide | Hansoh Pharmaceutical Group | phase 3 | 12 |
| UBT251 | The United Laboratories International | phase 3 | 12 |
| enicepatide | Hoffmann-La Roche | phase 3 | 10 |
| VK2735rule | Viking Therapeutics | phase 3 | 8 |
| NNC0519-0130 | Novo Nordisk | phase 2 | 11 |
| BI 3034701 | Boehringer Ingelheim | phase 2 | 6 |
| HRS-4729 | Jiangsu HengRui Medicine | phase 2 | 5 |
| NA-931rule | biomed-industries-inc | phase 2 | 3 |
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07928245Depressive Disorder, Major · United States, Bulgaria, Hungary and more | 2 | Not yet recruiting | May 2028 | 330 |
| NCT07775300Depressive Disorder, Major · United States, Australia, Brazil and more | 3 | Recruiting | Dec 2028 | 1,000 |
| NCT07759245Pulmonary Disease, Chronic Obstructive · United States, Argentina, Austria and more | 2 | Recruiting | May 2028 | 606 |
| NCT07545772Irritable Bowel Syndrome · United States, Belgium, Canada and more | 2 | Recruiting | Jul 2027 | 342 |
| NCT07545759Irritable Bowel Syndrome · United States, Belgium, Canada and more | 2 | Recruiting | Sep 2027 | 531 |
| NCT07476118Obesity · United States | 1 | Active, not recruiting | Feb 2027 | 150 |
| NCT07420283Opioid-Related Disorders · United States, Canada, Puerto Rico and more | 2 | Recruiting | Mar 2028 | 465 |
| NCT07412756Depressive Disorder, Major · United States, Australia, Brazil and more | 3 | Recruiting | Feb 2028 | 1,000 |
| NCT07410507Schizophrenia · United States, Argentina, Brazil and more | 2 | Recruiting | Nov 2027 | 450 |
| NCT07286175Bipolar Disorder · United States, Argentina, Brazil and more | 2 | Recruiting | Nov 2027 | 400 |
| NCT07223840Smoking · United States, China, Japan | 2 | Recruiting | Feb 2027 | 222 |
| NCT07219173Asthma · United States, Argentina, Brazil and more | 2 | Recruiting | Apr 2028 | 531 |
| NCT07219966Alcoholism · United States, Belgium, China and more | 3 | Recruiting | Apr 2028 | 1,100 |
| NCT07219953Alcoholism · United States, Belgium, China and more | 3 | Recruiting | Apr 2028 | 1,100 |
| NCT07202871Healthy · Singapore | 1 | Completed | Jul 17, 2026 | 47 |
| NCT07165015Renal Insufficiency · United States, New Zealand | 1 | Completed | Apr 16, 2026 | 31 |
| NCT07165002Hepatic Insufficiency · Hungary, New Zealand, Slovakia | 1 | Recruiting | Nov 2026 | 32 |
| NCT06606106Overweight · United States | 1 | Active, not recruiting | Nov 2026 | 302 |
| NCT04648865Healthy · Japan | 1 | Completed | Jun 4, 2021 | 40 |
How it is read
Names in the registry
- “Brenipatide”, 11 entries
- “LY3537031”, 10 entries
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 3 studies
- Irritable Bowel Syndrome, 2 studies
- Alcoholism, 2 studies
- Obesity, 2 studies
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.